AI-generated content for informational purposes only. Not financial advice. Always do your own research.

À propos

Becton Dickinson est une entreprise mondiale de technologie médicale qui fabrique des seringues, aiguilles, instruments de diagnostic, systèmes de gestion des médicaments et équipements de laboratoire utilisés par les institutions de santé du monde entier. L'entreprise est une Dividend Aristocrat avec plus de 50 années consécutives d'augmentations de dividendes, reflétant ses avantages concurrentiels durables et son portefeuille de produits essentiels. BDX attire les investisseurs à revenu qui souhaitent une exposition fiable au secteur des soins de santé.

Actions de premier ordre

Avec plus d'un siècle d'histoire opérationnelle, un réseau de distribution mondial atteignant les établissements de santé dans pratiquement tous les pays, et une croissance constante des bénéfices, Becton Dickinson est un blue chip fiable dans le secteur de la technologie médicale.

Actions à dividendes

Becton Dickinson est un Dividend Aristocrat avec plus de 50 années consécutives d'augmentations de dividendes annuels, soutenu par la nature non discrétionnaire de ses produits de fournitures médicales qui génèrent des flux de trésorerie stables dans n'importe quel environnement économique.

Actions de la sante

Becton Dickinson fournit les seringues, aiguilles, cathéters intraveineux, systèmes de diagnostic et plateformes de gestion des médicaments sur lesquels les hôpitaux et cliniques du monde entier dépendent quotidiennement, ce qui en fait un titre sanitaire indispensable.

Key Financials BDX

Prix $175.89
Variation (1J) -1.08%
Variation (30D) +15.28%
Variation (60D) +17.15%
Variation (90D) +16.53%
Variation (180D) +29.32%
Variation (1Y) -0.94%
Variation (5Y) -9.77%
P/E Ratio 12.65
EPS (TTM) $13.90
Plage sur 52 semaines $127.59 — $185.02
MA sur 50 jours $159.08
Volume 3.17M

Data updated Feb 15 · Source: Twelve Data

4.1
2 reviews
Market Position
4.7
Dividend Reliability
4.2
Valuation Attractiveness
4
Financial Stability
3.3
Management Quality
3.2
Long-Term Growth
2.5
Claude Opus 4.6
AI Review
3.7/5

Becton Dickinson is a global medical technology leader specializing in medical devices, instrument systems, and reagents. The company holds dominant positions in syringes, needles, and diagnostic systems, providing a durable competitive moat. At a P/E of 12.65 with EPS of $13.90, BDX appears attractively valued relative to healthcare peers, though this may reflect market concerns about growth trajectory.

The bull case centers on BD's essential product portfolio, recurring revenue streams, and recent strong momentum " up 29% over six months with the stock trading well above its 50-day moving average. The planned separation of its Biosciences segment could unlock shareholder value.

However, the bear case is notable: the stock is down nearly 10% over five years, significantly underperforming the broader market. Integration challenges from the Alaris infusion pump recall and elevated debt from acquisitions remain headwinds. The dividend yield, while supported by a 50+ year growth streak, is modest. BD offers defensive healthcare exposure but has struggled to deliver meaningful capital appreciation, making it better suited for income-oriented, conservative portfolios.

Market Position
4.7
Dividend Reliability
4.2
Valuation Attractiveness
4
Financial Stability
3.3
Management Quality
3.2
Long-Term Growth
2.5
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.5/5

Becton Dickinson (BDX) remains a cornerstone of the medical technology sector, providing essential consumables and diagnostic systems that create a wide economic moat. Currently trading significantly below its 52-week high and well under its 50-day moving average, the stock presents a potential value opportunity for contrarian investors. With a P/E ratio of approximately 13, BDX is priced attractively compared to historical norms and broader healthcare indices, suggesting the market has priced in significant pessimism. While the company faces near-term headwinds regarding margins and operational execution, its status as a Dividend Aristocrat underscores its financial resilience and long-term commitment to shareholder returns. For investors seeking a defensive healthcare play with reliable cash flows and limited downside risk at this valuation, BDX offers a compelling entry point, though patience may be required for a technical trend reversal.

Feb 12, 2026
Becton Dickinson Screenshot

Added: Feb 11, 2026

bd.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Chaque trader a une stratégie qui semble excellente dans sa tête. Le backtesting est la façon de découvrir si cela fonctionne réellement. Voici comment tester les stratégies correctement, quelles métriques comptent et pourquoi la plupart des résultats de backtesting sont trop beaux pour être vrais.